Literature DB >> 18457340

Genetic and phenotypic analysis of B-cell post-transplant lymphoproliferative disorders provides insights into disease biology.

Efsevia Vakiani1, Katia Basso, Ulf Klein, Mahesh M Mansukhani, Gopeshwar Narayan, Paula M Smith, Vundavalli V Murty, Riccardo Dalla-Favera, Laura Pasqualucci, Govind Bhagat.   

Abstract

B-cell post-transplant lymphoproliferative disorders (PTLD) are classified as early lesions, polymorphic lymphomas (P-PTLD) and monomorphic lymphomas (M-PTLD). These morphologic categories are thought to reflect a biologic continuum, although supporting genetic data are lacking. To gain better insights into PTLD pathogenesis, we characterized the phenotypes, immunoglobulin (Ig) gene alterations and non-Ig gene (BCL6, RhoH/TTF, c-MYC, PAX5, CIITA, BCL7A, PIM1) mutations of 21 PTLD, including an IM-like lesion, 8 P-PTLD and 12 M-PTLD. Gene expression profile analysis was also performed in 12 cases. All PTLD with clonal Ig rearrangements showed evidence of germinal centre (GC) transit based on the analysis of Ig and BCL6 gene mutations, and 74% had a non-GC phenotype (BCL6 +/- MUM1+). Although surface Ig abnormalities were seen in 6/19 (32%) PTLD, only three showed 'crippling' Ig mutations indicating other etiologies for loss of the B-cell receptor. Aberrant somatic hypermutation (ASHM) was almost exclusively observed in M-PTLD (8/12 vs. 1/8 P-PTLD) and all three recurrent cases analysed showed additional mutations in genes targeted by ASHM. Gene expression analysis showed distinct clustering of PTLD compared to B-cell non-Hodgkin lymphomas (B-NHL) without segregation of P-PTLD from non-GC M-PTLD or EBV+ from EBV- PTLD. The gene expression pattern of PTLD appeared more related to that of memory and activated B-cells. Together, our results suggest that PTLD represent a distinct type of B-NHL deriving from an antigen experienced B-cell, whose evolution is associated with accrual of genetic lesions. Copyright (c) 2008 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18457340     DOI: 10.1002/hon.859

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  26 in total

1.  Functional interplay of Epstein-Barr virus oncoproteins in a mouse model of B cell lymphomagenesis.

Authors:  Thomas Sommermann; Tomoharu Yasuda; Jonathan Ronen; Tristan Wirtz; Timm Weber; Ulrike Sack; Rebecca Caeser; Jingwei Zhang; Xun Li; Van Trung Chu; Anna Jauch; Kristian Unger; Daniel J Hodson; Altuna Akalin; Klaus Rajewsky
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-10       Impact factor: 11.205

Review 2.  Management of Non-Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder.

Authors:  Ajay Major; Manali Kamdar
Journal:  Curr Treat Options Oncol       Date:  2018-05-24

3.  Nodular pattern of bone marrow infiltration: frequent finding in immunosuppression-related EBV-associated large B-cell lymphomas.

Authors:  Deborah W Sevilla; Erin M Weeden; Suzy Alexander; Vundavalli V Murty; Bachir Alobeid; Govind Bhagat
Journal:  Virchows Arch       Date:  2009-10-06       Impact factor: 4.064

Review 4.  Systems biology of kidney diseases.

Authors:  John Cijiang He; Peter Y Chuang; Avi Ma'ayan; Ravi Iyengar
Journal:  Kidney Int       Date:  2011-08-31       Impact factor: 10.612

5.  Immune surveillance and therapy of lymphomas driven by Epstein-Barr virus protein LMP1 in a mouse model.

Authors:  Baochun Zhang; Sven Kracker; Tomoharu Yasuda; Stefano Casola; Matthew Vanneman; Cornelia Hömig-Hölzel; Zhe Wang; Emmanuel Derudder; Shuang Li; Tirtha Chakraborty; Shane E Cotter; Shohei Koyama; Treeve Currie; Gordon J Freeman; Jeffery L Kutok; Scott J Rodig; Glenn Dranoff; Klaus Rajewsky
Journal:  Cell       Date:  2012-02-17       Impact factor: 41.582

Review 6.  Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder.

Authors:  Margaret L Gulley; Weihua Tang
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

7.  p52 Activation in monomorphic B-cell posttransplant lymphoproliferative disorder/diffuse large B-cell lymphoma without BAFF-R expression.

Authors:  Alexis Proust; Patricia Rincé; Rita Creidy; Thierry Lazure; Irène Joab; Loïc Garçon; Monique Fabre; Catherine Guettier; Martine Raphael
Journal:  Am J Pathol       Date:  2011-08-24       Impact factor: 4.307

Review 8.  Posttransplant lymphoproliferative disease following liver transplantation.

Authors:  Kala Y Kamdar; Cliona M Rooney; Helen E Heslop
Journal:  Curr Opin Organ Transplant       Date:  2011-06       Impact factor: 2.640

Review 9.  Immunodeficiency-associated lymphoproliferative disorders: time for reappraisal?

Authors:  Yasodha Natkunam; Dita Gratzinger; Amy Chadburn; John R Goodlad; John K C Chan; Jonathan Said; Elaine S Jaffe; Daphne de Jong
Journal:  Blood       Date:  2018-08-06       Impact factor: 22.113

Review 10.  Epstein-Barr virus, rapamycin, and host immune responses.

Authors:  Sheri M Krams; Olivia M Martinez
Journal:  Curr Opin Organ Transplant       Date:  2008-12       Impact factor: 2.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.